At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression
In Brief
A Phase 2 clinical trial evaluating ITNK cell therapy for Anti-cancer Cell Immunotherapy and T Cell and NK Cell. Currently recruiting, targeting 60 participants across 1 site.
Detailed Summary
T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.
Study Details
Timeline
Interventions
Infusion of ITNK/CAR-ITNK cells